Could an allergy pill protect cancer patients from nerve pain?
NCT ID NCT07109817
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether desloratadine, a common allergy medication, can prevent nerve damage caused by taxane chemotherapy in breast cancer patients. About 116 participants will receive either desloratadine or a placebo for 12 weeks while on chemotherapy. The goal is to see if the drug reduces symptoms like numbness, tingling, or pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Desloratadine
- What this could lead to
- If it works, this could offer a simple, safe way to prevent nerve damage caused by taxane chemotherapy in breast cancer patients.
- What could go wrong
- This is a small Phase 2 trial, so results may not apply to everyone. The drug may not reduce nerve damage, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?